Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interleukin-2-containing regimen for newly treated smear-positive pulmonary tuberculosis
ChiCTR-IIR-17013878Phase 4Recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Jan 2015
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of aldesleukin in pulmonary tuberculosis (TB) (2 arms), sponsored by Beijing Chest Hospital. Primary endpoints: Time to sputum conversion and Sputum conversion rate at end of treatment. Started Jan 2015; status: recruiting.
02
Drugs
aldesleukin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR-IIR-17013878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17013878.